November 11, 2011Expert Review of Hematology
Treatment of warfarin-associated coagulopathy with vitamin K
Key result
Vitamin K replacement manages warfarin-associated coagulopathy, using low-dose oral (1-2.5 mg) for excessive INR without bleeding and high-dose IV (10 mg) with factor replacement for major bleeding.
Why the study?
How should vitamin K be dosed and administered to manage varying severities of warfarin-associated coagulopathy?
Population
Patients with warfarin-associated coagulopathy (WAC)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports severity-based vitamin K dosing in WAC; leaves open need for prospective trials to refine regimens.
Structured PICO
How should vitamin K be dosed and administered to manage varying severities of warfarin-associated coagulopathy?
P
Population
Patients with warfarin-associated coagulopathy (WAC)
I
Intervention
Vitamin K replacement (oral or intravenous, varying doses based on severity)
O
Outcome
Correction of international normalized ratio (INR) and management of bleeding
The dose and route of vitamin K administration for warfarin-associated coagulopathy should be tailored to the degree of INR elevation and the presence or absence of bleeding.
Cite This Study
Patriquin et al. (2011) conducted a review in Warfarin-associated coagulopathy. Vitamin K was evaluated. Vitamin K replacement manages warfarin-associated coagulopathy, using low-dose oral (1-2.5 mg) for excessive INR without bleeding and high-dose IV (10 mg) with factor replacement for major bleeding.